Management of chronic myeloid leukaemia: current treatment options, challenges, and future strategies
<p dir="ltr">Small molecule therapy is a critical component of targeted anticancer treatment, with tyrosine kinase inhibitors (TKIs) being the first compounds to treat the clonal Chronic Myelogenous Leukaemia (CML) translocation t (9;22) (q34; q11) effectively since 2001. TKIs, such...
محفوظ في:
| المؤلف الرئيسي: | |
|---|---|
| مؤلفون آخرون: | , , , , , , , , , , , |
| منشور في: |
2023
|
| الموضوعات: | |
| الوسوم: |
إضافة وسم
لا توجد وسوم, كن أول من يضع وسما على هذه التسجيلة!
|
| _version_ | 1864513527921770496 |
|---|---|
| author | Salma Younes (6424865) |
| author2 | Mohamed A. Ismail (418629) Rana Al-Jurf (14150016) Ayah Ziyada (17931443) Gheyath K. Nasrallah (9200525) Palli Valapila Abdulrouf (11619462) Mohamed Nagy (11874959) Hatem Zayed (835448) Thomas Farrell (3933833) Claudio Sorio (212799) Hisham Morsi (14152881) M. Walid Qoronfleh (14153088) Nader I. Al-Dewik (14152884) |
| author2_role | author author author author author author author author author author author author |
| author_facet | Salma Younes (6424865) Mohamed A. Ismail (418629) Rana Al-Jurf (14150016) Ayah Ziyada (17931443) Gheyath K. Nasrallah (9200525) Palli Valapila Abdulrouf (11619462) Mohamed Nagy (11874959) Hatem Zayed (835448) Thomas Farrell (3933833) Claudio Sorio (212799) Hisham Morsi (14152881) M. Walid Qoronfleh (14153088) Nader I. Al-Dewik (14152884) |
| author_role | author |
| dc.creator.none.fl_str_mv | Salma Younes (6424865) Mohamed A. Ismail (418629) Rana Al-Jurf (14150016) Ayah Ziyada (17931443) Gheyath K. Nasrallah (9200525) Palli Valapila Abdulrouf (11619462) Mohamed Nagy (11874959) Hatem Zayed (835448) Thomas Farrell (3933833) Claudio Sorio (212799) Hisham Morsi (14152881) M. Walid Qoronfleh (14153088) Nader I. Al-Dewik (14152884) |
| dc.date.none.fl_str_mv | 2023-04-20T03:00:00Z |
| dc.identifier.none.fl_str_mv | 10.1080/16078454.2023.2196866 |
| dc.relation.none.fl_str_mv | https://figshare.com/articles/journal_contribution/Management_of_chronic_myeloid_leukaemia_current_treatment_options_challenges_and_future_strategies/25183757 |
| dc.rights.none.fl_str_mv | CC BY 4.0 info:eu-repo/semantics/openAccess |
| dc.subject.none.fl_str_mv | Biological sciences Biochemistry and cell biology Biomedical and clinical sciences Cardiovascular medicine and haematology Clinical sciences Oncology and carcinogenesis Pharmacology and pharmaceutical sciences Tyrosine kinase inhibitors (TKIs) BCR::ABL1; Chronic Myeloid Leukaemia (CML) resistance therapeutic targets cancer personalized medicine precision medicine |
| dc.title.none.fl_str_mv | Management of chronic myeloid leukaemia: current treatment options, challenges, and future strategies |
| dc.type.none.fl_str_mv | Text Journal contribution info:eu-repo/semantics/publishedVersion text contribution to journal |
| description | <p dir="ltr">Small molecule therapy is a critical component of targeted anticancer treatment, with tyrosine kinase inhibitors (TKIs) being the first compounds to treat the clonal Chronic Myelogenous Leukaemia (CML) translocation t (9;22) (q34; q11) effectively since 2001. TKIs, such as imatinib, have improved the 10-year survival rate of CML patients to 80%. They bind the <i>BCR::ABL1</i> kinase and inhibit downstream signaling pathways. However, therapy failure may be seen in 20-25% of CML patients due to intolerance or inadequacy related to <i>BCR::ABL1</i> dependent or independent mechanisms. This review aimed to summarize current treatment options involving TKIs, resistance mechanisms and the prospective approaches to overcome TKI resistance. We highlight <i>BCR::ABL1</i>-dependent mechanisms of TKI resistance by reviewing clinically-documented <i>BCR::ABL1</i> mutations and their consequences for TKI binding. In addition, we summarize <i>BCR::ABL1</i> independent pathways, including the relevance of drug efflux, dysregulation of microRNA, and the involvement of alternative signaling pathways. We also discuss future approaches, such as gene-editing techniques in the context of CML, as potential therapeutic strategies.</p><h2>Other Information</h2><p dir="ltr">Published in: Hematology<br>License: <a href="http://creativecommons.org/licenses/by/4.0/" target="_blank">http://creativecommons.org/licenses/by/4.0/</a><br>See article on publisher's website: <a href="https://dx.doi.org/10.1080/16078454.2023.2196866" target="_blank">https://dx.doi.org/10.1080/16078454.2023.2196866</a></p> |
| eu_rights_str_mv | openAccess |
| id | Manara2_2cae41a8850414362c3121f341b0e45d |
| identifier_str_mv | 10.1080/16078454.2023.2196866 |
| network_acronym_str | Manara2 |
| network_name_str | Manara2 |
| oai_identifier_str | oai:figshare.com:article/25183757 |
| publishDate | 2023 |
| repository.mail.fl_str_mv | |
| repository.name.fl_str_mv | |
| repository_id_str | |
| rights_invalid_str_mv | CC BY 4.0 |
| spelling | Management of chronic myeloid leukaemia: current treatment options, challenges, and future strategiesSalma Younes (6424865)Mohamed A. Ismail (418629)Rana Al-Jurf (14150016)Ayah Ziyada (17931443)Gheyath K. Nasrallah (9200525)Palli Valapila Abdulrouf (11619462)Mohamed Nagy (11874959)Hatem Zayed (835448)Thomas Farrell (3933833)Claudio Sorio (212799)Hisham Morsi (14152881)M. Walid Qoronfleh (14153088)Nader I. Al-Dewik (14152884)Biological sciencesBiochemistry and cell biologyBiomedical and clinical sciencesCardiovascular medicine and haematologyClinical sciencesOncology and carcinogenesisPharmacology and pharmaceutical sciencesTyrosine kinase inhibitors (TKIs)BCR::ABL1;Chronic Myeloid Leukaemia (CML)resistancetherapeutic targetscancerpersonalized medicineprecision medicine<p dir="ltr">Small molecule therapy is a critical component of targeted anticancer treatment, with tyrosine kinase inhibitors (TKIs) being the first compounds to treat the clonal Chronic Myelogenous Leukaemia (CML) translocation t (9;22) (q34; q11) effectively since 2001. TKIs, such as imatinib, have improved the 10-year survival rate of CML patients to 80%. They bind the <i>BCR::ABL1</i> kinase and inhibit downstream signaling pathways. However, therapy failure may be seen in 20-25% of CML patients due to intolerance or inadequacy related to <i>BCR::ABL1</i> dependent or independent mechanisms. This review aimed to summarize current treatment options involving TKIs, resistance mechanisms and the prospective approaches to overcome TKI resistance. We highlight <i>BCR::ABL1</i>-dependent mechanisms of TKI resistance by reviewing clinically-documented <i>BCR::ABL1</i> mutations and their consequences for TKI binding. In addition, we summarize <i>BCR::ABL1</i> independent pathways, including the relevance of drug efflux, dysregulation of microRNA, and the involvement of alternative signaling pathways. We also discuss future approaches, such as gene-editing techniques in the context of CML, as potential therapeutic strategies.</p><h2>Other Information</h2><p dir="ltr">Published in: Hematology<br>License: <a href="http://creativecommons.org/licenses/by/4.0/" target="_blank">http://creativecommons.org/licenses/by/4.0/</a><br>See article on publisher's website: <a href="https://dx.doi.org/10.1080/16078454.2023.2196866" target="_blank">https://dx.doi.org/10.1080/16078454.2023.2196866</a></p>2023-04-20T03:00:00ZTextJournal contributioninfo:eu-repo/semantics/publishedVersiontextcontribution to journal10.1080/16078454.2023.2196866https://figshare.com/articles/journal_contribution/Management_of_chronic_myeloid_leukaemia_current_treatment_options_challenges_and_future_strategies/25183757CC BY 4.0info:eu-repo/semantics/openAccessoai:figshare.com:article/251837572023-04-20T03:00:00Z |
| spellingShingle | Management of chronic myeloid leukaemia: current treatment options, challenges, and future strategies Salma Younes (6424865) Biological sciences Biochemistry and cell biology Biomedical and clinical sciences Cardiovascular medicine and haematology Clinical sciences Oncology and carcinogenesis Pharmacology and pharmaceutical sciences Tyrosine kinase inhibitors (TKIs) BCR::ABL1; Chronic Myeloid Leukaemia (CML) resistance therapeutic targets cancer personalized medicine precision medicine |
| status_str | publishedVersion |
| title | Management of chronic myeloid leukaemia: current treatment options, challenges, and future strategies |
| title_full | Management of chronic myeloid leukaemia: current treatment options, challenges, and future strategies |
| title_fullStr | Management of chronic myeloid leukaemia: current treatment options, challenges, and future strategies |
| title_full_unstemmed | Management of chronic myeloid leukaemia: current treatment options, challenges, and future strategies |
| title_short | Management of chronic myeloid leukaemia: current treatment options, challenges, and future strategies |
| title_sort | Management of chronic myeloid leukaemia: current treatment options, challenges, and future strategies |
| topic | Biological sciences Biochemistry and cell biology Biomedical and clinical sciences Cardiovascular medicine and haematology Clinical sciences Oncology and carcinogenesis Pharmacology and pharmaceutical sciences Tyrosine kinase inhibitors (TKIs) BCR::ABL1; Chronic Myeloid Leukaemia (CML) resistance therapeutic targets cancer personalized medicine precision medicine |